Skip to main content

Table 4 Functional data for Placebo-control Group

From: Acute pharmacodynamic effects of pimobendan in client-owned cats with subclinical hypertrophic cardiomyopathy

 

Baseline

Post-placebo

P value

LAFS 2-D1 (mean% ± SD)

33.51 ± 4.00

31.95 ± 4.2

0.31

Mitral TDI S’1 (mean m/s ± SD)

0.07810 ± 0.0149

0.0767 ± 0.0234

0.83

LVOT Vmax2 [median m/s (IQR)]

1.03 (0.89, 2.32)

1.94 (1.12, 1.99)

0.22

RVOT Vmax1 (mean m/s ± SD)

1.02 ± 0.19

1.29 ± 0.29

0.01

HR at LVOT Vmax1 (mean bpm ± SD)

201.7 ± 20.55

209.3 ± 23.44

0.48

HR at RVOT Vmax1 (mean bpm ± SD)

187.3 ± 10.86

201.7 ± 25.64

0.10

  1. 1Paired T test
  2. 2Wilcoxon matched-pairs signed rank test
  3. LAFS, left atrial fractional shortening; 2-D, 2-dimensional echocardiography; SD, standard deviation; LVFS, left ventricular fractional shortening; TDI, tissue Doppler imaging; LVOT Vmax, left ventricular outflow tract maximal velocity, IQR interquartile range, RVOT Vmax, right ventricular outflow tract maximal velocity
Back to article page

BMC Veterinary Research

ISSN: 1746-6148

Contact us